(-)-3-(morpholin-4-ylmethyl)-5-methyl-7-(5,7-dibromonaphthylcarbonyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine methanesulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (-)-3-(morpholin-4-ylmethyl)-5-methyl-7-(5,7-dibromonaphthylcarbonyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine methanesulfonate
• 英文别名: (5,7-Dibromonaphthalen-1-yl)-[2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-5-yl]methanone;methanesulfonic acid
• 化学式: CH₄O₃S*C₂₇H₂₄Br₂N₂O₃
• 分子量: 680.414
• InChiKey: SKWODHBNAJWFQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.63
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  二氯乙基铝 、 5,7-dibromo-1-naphthalenecarboxylic acid chloride 、 (+)-3-(morpholin-4-ylmethyl)-5-methyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 在 sodium hydroxide 、 甲烷磺酸 作用下， 以 水 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 乙腈 为溶剂， 生成 (-)-3-(morpholin-4-ylmethyl)-5-methyl-7-(5,7-dibromonaphthylcarbonyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine methanesulfonate
  参考文献：
  名称：

  CB.sub.2 Receptor agonist compounds

  摘要：

  公开了使用公式（I）或（I'）的人类CB.sub.2受体特异性激动剂制备免疫调节药物。在公式（I）和（I'）中，R.sub.1是从--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11，--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11，--CHR.sub.9 CH.sub.2 NR'.sub.6 R'.sub.11，--(CH.sub.2).sub.n Z和--COR.sub.8中选择的一个基团；R'.sub.1是一个--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11或--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11基团；R.sub.2和R'.sub.2是氢，卤素或C.sub.1-4烷基；R.sub.3是氢，C.sub.1-4烷基或从--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11，--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11和--COR.sub.8中选择的一个基团；R'.sub.3是一个.dbd.CR.sub.6 R.sub.8基团；R.sub.4具有给出的R.sub.5的含义之一或是一个--COR.sub.8基团；R.sub.5是氢，C.sub.1-4烷基，C.sub.1-4烷氧基，卤素原子，CF.sub.3基团，OCF.sub.3基团或C.sub.1-4烷基硫基；R'.sub.5具有给出的R.sub.5的含义之一，并且位于茚环的第5或第6位置；R.sub.6是氢或C.sub.1-4烷基；R'.sub.6是C.sub.1-4烷基；R.sub.7具有给出的R.sub.5或R.sub.7的含义之一，且R.sub.9和R.sub.7一起形成一个通过Y连接到茚环的7位置的--Y--CH.sub.2--基团；R.sub.8是苯基，通过卤素，C.sub.1-4烷基或C.sub.1-4烷氧基取代一到四次；从萘-1-基，萘-2-基，1,2,3,4-四氢萘-1-基，1,2,3,4-四氢萘-5-基，蒽基，苯并呋喃基，苯并噻吩-2-基，苯并噻吩-3-基，2-, 3-, 4-或8-喹啉基中选择的多环环，所述多环环可以选择地被C.sub.1-4烷基，C.sub.1-4烷氧基，C.sub.1-4烷硫基，卤素，氰基，羟基，三氟甲基和咪唑-1-基取代一次或两次；R.sub.10和R.sub.11一起是从--CH.sub.2--O--CH.sub.2--CR.sub.12 R.sub.13--和--(CH.sub.2).sub.p--CR.sub.12 R.sub.13--中选择的一个基团，其中由R.sub.12和R.sub.13取代的碳原子连接到氮原子；R'.sub.11是C.sub.1-4烷基；或R'.sub.11和R'.sub.6，与它们连接的氮原子一起形成从吗啉-4-基，硫代吗啉-4-基，哌啶-1-基和吡咯啉-1-基中选择的一个基团；R.sub.12和R.sub.13中的每一个独立地是氢或C.sub.1-4烷基；n为2、3、4或5；p为2或3；Z为甲基基团或卤素原子；Y为亚甲基基团或氧原子。

  公开号：

  US06013648A1

文献信息

• US6013648A
  申请人：——

  公开号：US6013648A

  公开（公告）日：2000-01-11
• CB.sub.2 Receptor agonist compounds
  申请人：Sanofi

  公开号：US06013648A1

  公开（公告）日：2000-01-11

  The use of human CB.sub.2 receptor-specific agonists of formula (I) or (I') for preparing immunomodulating drugs is disclosed. In formulae (I) and (I'), R.sub.1 is a group selected from --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11, --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11, --CHR.sub.9 CH.sub.2 NR'.sub.6 R'.sub.11, --(CH.sub.2).sub.n Z and --COR.sub.8 ; R'.sub.1 is a --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11 or --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11 group; R.sub.2 and R'.sub.2 are hydrogen, halogen or C.sub.1-4 alkyl; R.sub.3 is hydrogen, C.sub.1-4 alkyl or a group selected from --CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11, --(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11 and --COR.sub.8 ; R'.sub.3 is a .dbd.CR.sub.6 R.sub.8 group; R.sub.4 has one of the meanings given for R.sub.5 or is a --COR.sub.8 group; R.sub.5 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, a halogen atom, a CF.sub.3 group, an OCF.sub.3 group or C.sub.1-4 alkylthio; R'.sub.5 has one of the meanings given for R.sub.5 and is in the 5 or 6 position of the indene ring; R.sub.6 is hydrogen or C.sub.1-4 alkyl; R'.sub.6 is C.sub.1-4 alkyl; R.sub.7 has one of the meanings given for R.sub.5 or R.sub.7 and R.sub.9 together form a --Y--CH.sub.2 -- group attached to the indole ring in the 7 position by a group Y; R.sub.8 is phenyl substituted one to four times by a substituent selected from halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy; a polycyclic ring selected from naphth-1-yl, naphth-2-yl, 1,2,3,4-tetrahydronaphth-1-yl, 1,2,3,4-tetrahydronaphth-5-yl, anthryl, benzofuryl, benzothien-2-yl, benzothien-3-yl, 2-, 3-, 4- or 8-quinolyl, said polycyclic rings optionally being substituted once or twice by a substituent selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halogen, cyano, hydroxyl, trifluoromethyl and imidazol-1-yl; R.sub.10 and R.sub.11 together are a group selected from --CH.sub.2 --O--CH.sub.2 --CR.sub.12 R.sub.13 -- and --(CH.sub.2).sub.p --CR.sub.12 R.sub.13 --, wherein the carbon atom substituted by R.sub.12 and R.sub.13 is attached to the nitrogen atom; R'.sub.11 is C.sub.1-4 alkyl; or R'.sub.11 and R'.sub.6, taken together with the nitrogen atom to which they are attached, form a group selected from morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl and pyrrolidin-1-yl; each of R.sub.12 and R.sub.13 is independently hydrogen or C.sub.1-4 alkyl; n is 2, 3, 4 or 5; p is 2 or 3; Z is a methyl group or a halogen atom; and Y is a methylene group or an oxygen atom.

  公开了使用公式（I）或（I'）的人类CB.sub.2受体特异性激动剂制备免疫调节药物。在公式（I）和（I'）中，R.sub.1是从--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11，--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11，--CHR.sub.9 CH.sub.2 NR'.sub.6 R'.sub.11，--(CH.sub.2).sub.n Z和--COR.sub.8中选择的一个基团；R'.sub.1是一个--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11或--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11基团；R.sub.2和R'.sub.2是氢，卤素或C.sub.1-4烷基；R.sub.3是氢，C.sub.1-4烷基或从--CH.sub.2 CHR.sub.10 NR.sub.6 R.sub.11，--(CH.sub.2).sub.2 NR'.sub.6 R'.sub.11和--COR.sub.8中选择的一个基团；R'.sub.3是一个.dbd.CR.sub.6 R.sub.8基团；R.sub.4具有给出的R.sub.5的含义之一或是一个--COR.sub.8基团；R.sub.5是氢，C.sub.1-4烷基，C.sub.1-4烷氧基，卤素原子，CF.sub.3基团，OCF.sub.3基团或C.sub.1-4烷基硫基；R'.sub.5具有给出的R.sub.5的含义之一，并且位于茚环的第5或第6位置；R.sub.6是氢或C.sub.1-4烷基；R'.sub.6是C.sub.1-4烷基；R.sub.7具有给出的R.sub.5或R.sub.7的含义之一，且R.sub.9和R.sub.7一起形成一个通过Y连接到茚环的7位置的--Y--CH.sub.2--基团；R.sub.8是苯基，通过卤素，C.sub.1-4烷基或C.sub.1-4烷氧基取代一到四次；从萘-1-基，萘-2-基，1,2,3,4-四氢萘-1-基，1,2,3,4-四氢萘-5-基，蒽基，苯并呋喃基，苯并噻吩-2-基，苯并噻吩-3-基，2-, 3-, 4-或8-喹啉基中选择的多环环，所述多环环可以选择地被C.sub.1-4烷基，C.sub.1-4烷氧基，C.sub.1-4烷硫基，卤素，氰基，羟基，三氟甲基和咪唑-1-基取代一次或两次；R.sub.10和R.sub.11一起是从--CH.sub.2--O--CH.sub.2--CR.sub.12 R.sub.13--和--(CH.sub.2).sub.p--CR.sub.12 R.sub.13--中选择的一个基团，其中由R.sub.12和R.sub.13取代的碳原子连接到氮原子；R'.sub.11是C.sub.1-4烷基；或R'.sub.11和R'.sub.6，与它们连接的氮原子一起形成从吗啉-4-基，硫代吗啉-4-基，哌啶-1-基和吡咯啉-1-基中选择的一个基团；R.sub.12和R.sub.13中的每一个独立地是氢或C.sub.1-4烷基；n为2、3、4或5；p为2或3；Z为甲基基团或卤素原子；Y为亚甲基基团或氧原子。